Literature DB >> 8751034

Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients.

H Russo1, J Brès, M P Duboin, B Roquefeuil.   

Abstract

Thiopental was administered to neurosurgical patients for cerebral protection and its pharmacokinetic parameters were determined after a single bolus of 540, 1000 or 1500 mg (3 subjects) or after multiple doses of 250 mg (5 subjects) and 500 mg (2 subjects) every two hours for up to 7 days. The data were analysed by a two- or three-compartment model and linear kinetics. After a single iv bolus, the mean initial volume of distribution (V1) was 0.481 l.kg-1, and the steady-state volume of distribution (Vss) was 2.16 l.kg-1. The distribution (t1/2 alpha) and elimination (t1/2 beta) half-lives were 0.590 and 5.89 h, respectively, and the mean residence time (MRT) was 7.44 h. The clearance was 5.41 ml.min-1.kg-1. With repeated injections, the pharmacokinetic parameters for each patient were estimated taking into account all administered doses and blood samples, which were taken whenever possible daily at steady state and after the last dose. The variability observed in the pharmacokinetic parameters of thiopental reflected by the coefficient of variation (CV%) was wide but was of similar magnitude within patients (CVintra) as it was between patients (CVinter). The steady-state trough plasma concentration (Cmin obs) ranged from 4.8 to 30 mg.l-1 (mean 16.0 mg.l-1 and median 14.3 mg.l-1). Peak concentrations (Cmax obs) ranged from 8.35 to 45 mg.l-1 (25.4 mg.l-1, and median 23.3 mg.l-1). The values of V1 and Vss were similar to those obtained after a single dose. For V1, the mean was 0.333 l.kg-1. The mean Vss was 2.68 l.kg-1, with a CVintra of 12.6 to 56% and a CVinter of 13.2%. A shorter distribution half-life t1/2 alpha was noted on multiple dosing; the mean value was 0.122 h. The elimination half-life t1/2 beta and the mean residence time became longer due to a decrease in clearance. For t1/2 beta the mean value was 16.3 h. The mean MRT was 21.9 h, CVintra 9.19 to 48.5%, and the CVinter 35.3%. The mean clearance was 2.16 ml.min-1.kg-1, CVintra 7.28 to 25.5%, and the CVinter 20.4%. This value is 50% lower than after a single dose. Identification of the kinetic parameters of thiopental allows simulation of the effects of doses on subsequent plasma levels and will permit a priori prediction of day to day adjustment of drug dosage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8751034     DOI: 10.1007/bf00192371

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  31 in total

1.  The fate of thiopental in man and a method for its estimation in biological material.

Authors:  B B BRODIE; L C MARK
Journal:  J Pharmacol Exp Ther       Date:  1950-01       Impact factor: 4.030

2.  Protein binding of drugs in plasma from patients with acute renal failure.

Authors:  F Andreasen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1973

3.  Pharmacokinetics and plasma binding of thiopental. I: Studies in surgical patients.

Authors:  D J Morgan; G L Blackman; J D Paull; L J Wolf
Journal:  Anesthesiology       Date:  1981-06       Impact factor: 7.892

4.  Pharmacokinetics of high-dose thiopental used in cerebral resuscitation.

Authors:  D R Stanski; F G Mihm; M H Rosenthal; S M Kalman
Journal:  Anesthesiology       Date:  1980-08       Impact factor: 7.892

5.  Pharmacokinetic properties of thiopental in two patients treated for uncontrollable seizures.

Authors:  J C Cloyd; B D Wright; D Perrier
Journal:  Epilepsia       Date:  1979-06       Impact factor: 5.864

6.  Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery.

Authors:  M M Ghoneim; M J Van Hamme
Journal:  Br J Anaesth       Date:  1978-12       Impact factor: 9.166

7.  Thiopental disposition as a function of age in female patients undergoing surgery.

Authors:  D Jung; M Mayersohn; D Perrier; J Calkins; R Saunders
Journal:  Anesthesiology       Date:  1982-04       Impact factor: 7.892

8.  The role of metabolism and protein binding in thiopental anesthesia.

Authors:  P G Burch; D R Stanski
Journal:  Anesthesiology       Date:  1983-02       Impact factor: 7.892

9.  Thiopentone sensitivity in young and elderly women.

Authors:  J H Christensen; F Andreasen; J A Jansen
Journal:  Br J Anaesth       Date:  1983-01       Impact factor: 9.166

10.  Pharmacokinetics and anesthetic potency of a thiopental isomer.

Authors:  D R Stanski; P G Burch; S Harapat; R K Richards
Journal:  J Pharm Sci       Date:  1983-08       Impact factor: 3.534

View more
  5 in total

Review 1.  Pharmacodynamics and pharmacokinetics of thiopental.

Authors:  H Russo; F Bressolle
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

2.  Time-dependent pharmacokinetics of high dose thiopental infusion in intensive care patients.

Authors:  H Russo; M P Dubboin; F Bressolle; S Urien
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

3.  Interaction of thiopental with esomeprazole in critically ill patients.

Authors:  Amélie Marsot; Françoise Goirand; Nadine Milési; Monique Dumas; Audrey Boulamery; Nicolas Simon
Journal:  Eur J Clin Pharmacol       Date:  2013-05-30       Impact factor: 2.953

Review 4.  Pharmacokinetic alterations after severe head injury. Clinical relevance.

Authors:  B A Boucher; S D Hanes
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

5.  BPC 157 antagonized the general anaesthetic potency of thiopental and reduced prolongation of anaesthesia induced by L-NAME/thiopental combination.

Authors:  Mladen Zemba; Andrea Zemba Cilic; Igor Balenovic; Matija Cilic; Bozo Radic; Jelena Suran; Domagoj Drmic; Antonio Kokot; Vasilije Stambolija; Tamara Murselovic; Jadranka Katancic Holjevac; Sandra Uzun; Viktor Djuzel; Josipa Vlainic; Sven Seiwerth; Predrag Sikiric
Journal:  Inflammopharmacology       Date:  2015-11-13       Impact factor: 4.473

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.